Three G-protein-coupled receptors sit at the center of nearly every metabolic-research peptide discussion: GLP-1, GIP, and the glucagon receptor. They're structurally related, they signal through overlapping intracellular pathways, and the number of them a given compound engages is the single biggest differentiator between the major research peptides in this space.
GLP-1: the reference incretin receptor
The glucagon-like peptide-1 receptor is expressed in pancreatic islet cells, the gastrointestinal tract, and regions of the central nervous system. In research models, GLP-1 receptor activation is studied for its role in glucose-dependent insulin secretion, gastric emptying, and satiety signaling. It's a class B GPCR, signaling primarily through Gs-protein coupling and downstream cAMP/PKA activation. Semaglutide is the reference GLP-1-selective agonist used in this research area; see its research overview for structural detail.
GIP: the second incretin
The glucose-dependent insulinotropic polypeptide receptor is the other classical incretin receptor, expressed alongside GLP-1 in the gut and pancreas but with distinct downstream effects researchers are still actively mapping — including questions about its role in adipose tissue signaling that don't have a clean GLP-1 parallel. Compounds engaging both receptors are studied specifically to characterize whether combined GIP/GLP-1 agonism produces effects that neither receptor alone reproduces. Tirzepatide is the primary dual agonist used in this line of research; see the tirzepatide research overview.
Glucagon receptor: the third target
The glucagon receptor is more distantly related within the same class B family and is classically associated with hepatic glucose output and energy-expenditure pathways rather than insulin secretion directly. Adding glucagon receptor agonism to a GIP/GLP-1 backbone is what defines the triple-agonist research category. Retatrutide is the compound studied for this triple-receptor profile; its research overview and the retatrutide vs. tirzepatide comparison cover how the added receptor reshapes the research questions being asked.
Why receptor count is the organizing framework
Because these three receptors share signaling machinery but differ in tissue distribution and downstream effect, the cleanest way to compare compounds in this class isn't potency or formulation — it's simply which receptors a given molecule engages. That framework is explored further in our broader overview of GLP-1 receptor agonists in metabolic research, which looks at the compounds themselves rather than the receptor biology alone.
Why researchers track receptor selectivity so closely
Receptor selectivity isn't a minor footnote in this research area — it's the main variable that determines what a given experimental model can actually answer. A compound that engages only GLP-1 isolates that pathway cleanly, which is useful when the research question is specific to GLP-1 signaling alone. A dual or triple agonist, by contrast, is the right tool when the question is about how multiple incretin pathways interact or compound their effects on a shared downstream target, such as cAMP accumulation in a given cell model. Selecting the wrong compound for the question — say, a GLP-1-only agonist in a study specifically designed to probe GIP-receptor contribution — doesn't just weaken the result, it can make the data uninterpretable relative to the original hypothesis. That's the practical reason this receptor framework, more than any other single fact about these molecules, tends to be the first thing researchers new to metabolic peptide work need to internalize.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.